iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Alembic Pharmaceuticals receives USFDA tentative approval for Vortioxetine Tablets

12 Jan 2022 , 01:34 AM

Alembic Pharmaceuticals today announced that it has received tentative approval from the US Food Drug Administration USFDA for its Abbreviated New Drug Application ANDA for Vortioxetine Tablets 5 mg 10 mg 15 mg and 20 mg The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product RLD Trintellix Tablets 5 mg 10 mg 15 mg and 20 mg of Takeda Pharmaceuticals USA lnc Takeda Vortioxetine Tablets are indicated for the treatment of major depressive disorder MOD Vortioxetine Tablets 5 mg 10 mg 15 mg and 20 mg have an estimated market size of US$ 1249 million for twelve months ending September 2021 according to IQVIA Alembic is currently in litigation with HLundbeck in Court of Appeals for the Federal Circuit and launch of the product will depend on litigation outcome

Related Tags

  • Announcements
  • BSE
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.